Vanda Pharmaceuticals Inc. (FRA:VM4)

Market Cap	255.19M
Revenue (ttm)	180.75M
Net Income (ttm)	-71.76M
Shares Out	n/a
EPS (ttm)	-1.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	311
Open	4.540
Previous Close	4.540
Day's Range	4.540 - 4.540
52-Week Range	3.460 - 4.880
Beta	n/a
RSI	60.58
Earnings Date	Feb 12, 2026

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 368
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: VM4

Financial Performance

Financial numbers in USD